# Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer

> **NCT03029533** · PHASE1 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 44 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Leuprolide Acetate
- **DRUG:** Leuprolide Acetate

## Key facts

- **NCT ID:** NCT03029533
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02
- **Primary completion:** 2017-11
- **Final completion:** —
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029533, "Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT03029533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*